Characterization of lysosome-destabilizing DOPE/PLGA nanoparticles designed for cytoplasmic drug release

Int J Pharm. 2014 Aug 25;471(1-2):349-57. doi: 10.1016/j.ijpharm.2014.05.054. Epub 2014 Jun 2.

Abstract

Polymeric nanoparticles (NPs) offer a promising approach for therapeutic intracellular delivery of proteins, conventionally hampered by short half-lives, instability and immunogenicity. Remarkably, NPs uptake occurs via endocytic internalization leading to NPs content's release within lysosomes. To overcome lysosomal degradation and achieve NPs and/or loaded proteins release into cytosol, we propose the formulation of hybrid NPs by adding 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) as pH sensitive component in the formulation of poly-lactide-co-glycolide (PLGA) NPs. Hybrid NPs, featured by different DOPE/PLGA ratios, were characterized in terms of structure, stability and lipid organization within the polymeric matrix. Experiments on NIH cells and rat primary neuronal cultures highlighted the safety profile of hybrid NPs. Moreover, after internalization, NPs are able to transiently destabilize the integrity of lysosomes in which they are taken up, speeding their escape and favoring cytoplasmatic localization. Thus, these DOPE/PLGA-NPs configure themselves as promising carriers for intracellular protein delivery.

Keywords: DOPE; Drug delivery; Endo-lysosomes; Nanoparticles (NPs); PLGA; Stability.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Cell Survival / drug effects
  • Cytoplasm / metabolism*
  • Drug Carriers / chemistry*
  • Drug Carriers / pharmacokinetics
  • Drug Carriers / toxicity
  • Drug Liberation
  • Drug Stability
  • Drug Storage
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism
  • Lactic Acid / chemistry*
  • Lactic Acid / pharmacokinetics
  • Lactic Acid / toxicity
  • Lysosomes / drug effects*
  • Lysosomes / metabolism
  • Mice, Inbred Strains
  • Nanoparticles / chemistry*
  • Nanoparticles / toxicity
  • Neurons / drug effects
  • Neurons / metabolism
  • Phosphatidylethanolamines / chemistry*
  • Phosphatidylethanolamines / pharmacokinetics
  • Phosphatidylethanolamines / toxicity
  • Polyglycolic Acid / chemistry*
  • Polyglycolic Acid / pharmacokinetics
  • Polyglycolic Acid / toxicity
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Primary Cell Culture
  • Rats
  • Serum Albumin, Bovine / administration & dosage*
  • Serum Albumin, Bovine / pharmacokinetics
  • Serum Albumin, Bovine / toxicity
  • Surface Properties

Substances

  • 1,2-dioleoyl-glycero-3-phosphatidyl ethanolamine
  • Drug Carriers
  • Phosphatidylethanolamines
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Serum Albumin, Bovine
  • Lactic Acid